Abstract
Gallbladder carcinoma (GBC) is a malignancy with an extremely poor prognosis. In order to improve the survival rate, identification of new susceptibility risk factors is of importance. Here, we report findings on the novel cancer-related gene lysosomal protein transmembrane 4 beta (LAPTM4B) that has two alleles designated LAPTM4B*1 and LAPTM4B*2. Allele *1 differs from allele *2 in that it contains one copy of a 19-bp sequence, whereas this sequence is duplicated in exon 1 of allele *2. This study aimed to investigate the relationship of LAPTM4B allelic variation and GBC susceptibility. LAPTM4B genotype was analyzed in 155 healthy individuals and 91 GBC patients by PCR, and the genotypic distribution of LAPTM4B was analyzed with the chi-squared test. The frequency of allele *2 was 37.9 and 24.8% in the GBC and the control groups, respectively, representing a significant difference between these two groups (P < 0.001). LAPTM4B allele *2 may be a risk factor associated with genetic susceptibility to GBC.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Wood R, Fraser LA, Brewster DH, et al. Epidemiology of gallbladder cancer and trends in cholecystectomy rates in Scotland, 1968–1998. Eur J Cancer. 2003;39:2080–6.
Diamantis I, Karamitopoulou E, Perentes E, et al. p53 protein immunoreactivity in extrahepatic bile duct and gallbladder cancer: correlation with tumor grade and survival. Hepatology. 1995;22:774–9.
Carriaga MT, Henson DE. Liver, gallbladder, extrahepatic bile ducts, and pancreas. Cancer. 1995;75:171–90.
Abi-Rached B, Neugut AI. Diagnostic and management issues in gallbladder carcinoma. Oncology. 1995;9:19–24.
Hui AM, Li X, Shi YZ, et al. Cyclin D1 overexpression is a critical event in gallbladder carcinogenesis and independently predicts decreased survival for patients with gallbladder carcinoma. Clin Cancer Res. 2000;6:4272–7.
Hui AM, Li X, Shi YZ, et al. p27(Kip1) expression in normal epithelia, precancerous lesions, and carcinomas of the gallbladder: association with cancer progression and prognosis. Hepatology. 2000;31:1068–72.
Singh MK, Chetri K, Pandey UB, et al. Mutational spectrum of K-ras oncogene among Indian patients with gallbladder cancer. J Gastroenterol Hepatol. 2004;19:916–21.
Shao G, Zhou R, Zhang Q, et al. Molecular cloning and characterization of LAPTM4B, a novel gene upregulated in hepatocellular carcinoma. Oncogene. 2003;22:5060–9.
Lee HM, Zhang H, Schulz V, et al. Downstream targets of HOXB4 in a cell line model of primitive hematopoietic progenitor cells. Blood. 2010;116:720–30.
Yang H, Xiong F, Wei X, et al. Overexpression of LAPTM4B-35 promotes growth and metastasis of hepatocellular carcinoma in vitro and in vivo. Cancer Lett. 2010;294:236–44.
Zhou L, He X, Yu J, et al. Expression of LAPTM4B in gallbladder carcinoma cells: the role in invasive potential. Hepatogastroenterology. 2010;57:207–11.
Yang H, Xiong F, Qi R, et al. LAPTM4B-35 is a novel prognostic factor of hepatocellular carcinoma. J Surg Oncol. 2010;101:363–9.
Yang H, Xiong F, Lin M, et al. LAPTM4B-35 overexpression is a risk factor for tumor recurrence and poor prognosis in hepatocellular carcinoma. J Cancer Res Clin Oncol. 2010;136:275–81.
Meng F, Yin M, Song H, et al. LAPTM4B-35 overexpression is an independent prognostic marker in endometrial carcinoma. Int J Gynecol Cancer. 2010;20:745–50.
Meng F, Luo C, Hu Y, et al. Overexpression of LAPTM4B-35 in cervical carcinoma: a clinicopathologic study. Int J Gynecol Pathol. 2010;29:587–93.
Yin M, Xu Y, Lou G, et al. LAPTM4B overexpression is a novel predictor of epithelial ovarian carcinoma metastasis. Int J Cancer. 2011;129:629–35.
Li Y, Zou L, Li Q, et al. Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Nat Med. 2010;16:214–8.
Zhou L, He X, Yu J, et al. Overexpression of LAPTM4B promotes growth of gallbladder carcinoma cells in vitro. Am J Surg. 2010;199:515–21.
Yang Y, Yang H, McNutt MA, et al. LAPTM4B overexpression is an independent prognostic marker in ovarian carcinoma. Oncol Rep. 2008;20:1077–83.
Zhou L, He X, Cui Q, et al. Expression of LAPTM4B-35: a novel marker of progression, invasiveness and poor prognosis of extrahepatic cholangiocarcinoma. Cancer Lett. 2008;264:209–17.
Zhou L, He X, Chen J, et al. Overexpression of LAPTM4B-35 closely correlated with clinicopathological features and post-resectional survival of gallbladder carcinoma. Eur J Cancer. 2007;43:809–15.
Liu X, Xiong F, Wei X, et al. LAPTM4B-35, a novel tetratransmembrane protein and its PPRP motif play critical roles in proliferation and metastatic potential of hepatocellular carcinoma cells. Cancer Sci. 2009;100:2335–40.
Acknowledgments
This work was supported by grants from the National Nature Science Fund (No. 31000622) and Specialized Research Fund for the Doctoral Program of Higher Education of China (20100001120043).
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yang, H., Zhai, G., Ji, X. et al. Correlation of LAPTM4B polymorphisms with gallbladder carcinoma susceptibility in Chinese patients. Med Oncol 29, 2809–2813 (2012). https://doi.org/10.1007/s12032-012-0173-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12032-012-0173-4